An Innovative High-Throughput Screening Approach for Discovery of Small Molecules That Inhibit TNF Receptors

Chih Hung Lo, Nagamani Vunnam, Andrew K Lewis, Ting Lan Chiu, Benjamin E. Brummel, Tory M. Schaaf, Benjamin D. Grant, Prachi Bawaskar, David D Thomas, Jonathan N Sachs

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Tumor necrosis factor receptor 1 (TNFR1) is a transmembrane receptor that binds tumor necrosis factor or lymphotoxin-alpha and plays a critical role in regulating the inflammatory response. Upregulation of these ligands is associated with inflammatory and autoimmune diseases. Current treatments reduce symptoms by sequestering free ligands, but this can cause adverse side effects by unintentionally inhibiting ligand binding to off-target receptors. Hence, there is a need for new small molecules that specifically target the receptors, rather than the ligands. Here, we developed a TNFR1 FRET biosensor expressed in living cells to screen compounds from the NIH Clinical Collection. We used an innovative high-throughput fluorescence lifetime screening platform that has exquisite spatial and temporal resolution to identify two small-molecule compounds, zafirlukast and triclabendazole, that inhibit the TNFR1-induced IκBα degradation and NF-κB activation. Biochemical and computational docking methods were used to show that zafirlukast disrupts the interactions between TNFR1 pre-ligand assembly domain (PLAD), whereas triclabendazole acts allosterically. Importantly, neither compound inhibits ligand binding, proving for the first time that it is possible to inhibit receptor activation by targeting TNF receptor–receptor interactions. This strategy should be generally applicable to other members of the TNFR superfamily, as well as to oligomeric receptors in general.

Original languageEnglish (US)
Pages (from-to)950-961
Number of pages12
JournalSLAS Discovery
Volume22
Issue number8
DOIs
StatePublished - Sep 1 2017

Fingerprint

Tumor Necrosis Factor Receptors
Screening
triclabendazole
Throughput
Ligands
Molecules
Chemical activation
Lymphotoxin-alpha
Biosensing Techniques
Biosensors
Autoimmune Diseases
Up-Regulation
Tumor Necrosis Factor-alpha
Fluorescence
Cells
Degradation

Keywords

  • NF-κB inhibition
  • pre-ligand assembly domain
  • receptor–receptor interaction
  • time-resolved FRET
  • tumor necrosis factor receptor 1

Cite this

An Innovative High-Throughput Screening Approach for Discovery of Small Molecules That Inhibit TNF Receptors. / Lo, Chih Hung; Vunnam, Nagamani; Lewis, Andrew K; Chiu, Ting Lan; Brummel, Benjamin E.; Schaaf, Tory M.; Grant, Benjamin D.; Bawaskar, Prachi; Thomas, David D; Sachs, Jonathan N.

In: SLAS Discovery, Vol. 22, No. 8, 01.09.2017, p. 950-961.

Research output: Contribution to journalArticle

@article{3a16d80c62774d7f8c8abd168d252df1,
title = "An Innovative High-Throughput Screening Approach for Discovery of Small Molecules That Inhibit TNF Receptors",
abstract = "Tumor necrosis factor receptor 1 (TNFR1) is a transmembrane receptor that binds tumor necrosis factor or lymphotoxin-alpha and plays a critical role in regulating the inflammatory response. Upregulation of these ligands is associated with inflammatory and autoimmune diseases. Current treatments reduce symptoms by sequestering free ligands, but this can cause adverse side effects by unintentionally inhibiting ligand binding to off-target receptors. Hence, there is a need for new small molecules that specifically target the receptors, rather than the ligands. Here, we developed a TNFR1 FRET biosensor expressed in living cells to screen compounds from the NIH Clinical Collection. We used an innovative high-throughput fluorescence lifetime screening platform that has exquisite spatial and temporal resolution to identify two small-molecule compounds, zafirlukast and triclabendazole, that inhibit the TNFR1-induced IκBα degradation and NF-κB activation. Biochemical and computational docking methods were used to show that zafirlukast disrupts the interactions between TNFR1 pre-ligand assembly domain (PLAD), whereas triclabendazole acts allosterically. Importantly, neither compound inhibits ligand binding, proving for the first time that it is possible to inhibit receptor activation by targeting TNF receptor–receptor interactions. This strategy should be generally applicable to other members of the TNFR superfamily, as well as to oligomeric receptors in general.",
keywords = "NF-κB inhibition, pre-ligand assembly domain, receptor–receptor interaction, time-resolved FRET, tumor necrosis factor receptor 1",
author = "Lo, {Chih Hung} and Nagamani Vunnam and Lewis, {Andrew K} and Chiu, {Ting Lan} and Brummel, {Benjamin E.} and Schaaf, {Tory M.} and Grant, {Benjamin D.} and Prachi Bawaskar and Thomas, {David D} and Sachs, {Jonathan N}",
year = "2017",
month = "9",
day = "1",
doi = "10.1177/2472555217706478",
language = "English (US)",
volume = "22",
pages = "950--961",
journal = "SALAS Discovery",
issn = "2472-5552",
publisher = "Sage Publications",
number = "8",

}

TY - JOUR

T1 - An Innovative High-Throughput Screening Approach for Discovery of Small Molecules That Inhibit TNF Receptors

AU - Lo, Chih Hung

AU - Vunnam, Nagamani

AU - Lewis, Andrew K

AU - Chiu, Ting Lan

AU - Brummel, Benjamin E.

AU - Schaaf, Tory M.

AU - Grant, Benjamin D.

AU - Bawaskar, Prachi

AU - Thomas, David D

AU - Sachs, Jonathan N

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Tumor necrosis factor receptor 1 (TNFR1) is a transmembrane receptor that binds tumor necrosis factor or lymphotoxin-alpha and plays a critical role in regulating the inflammatory response. Upregulation of these ligands is associated with inflammatory and autoimmune diseases. Current treatments reduce symptoms by sequestering free ligands, but this can cause adverse side effects by unintentionally inhibiting ligand binding to off-target receptors. Hence, there is a need for new small molecules that specifically target the receptors, rather than the ligands. Here, we developed a TNFR1 FRET biosensor expressed in living cells to screen compounds from the NIH Clinical Collection. We used an innovative high-throughput fluorescence lifetime screening platform that has exquisite spatial and temporal resolution to identify two small-molecule compounds, zafirlukast and triclabendazole, that inhibit the TNFR1-induced IκBα degradation and NF-κB activation. Biochemical and computational docking methods were used to show that zafirlukast disrupts the interactions between TNFR1 pre-ligand assembly domain (PLAD), whereas triclabendazole acts allosterically. Importantly, neither compound inhibits ligand binding, proving for the first time that it is possible to inhibit receptor activation by targeting TNF receptor–receptor interactions. This strategy should be generally applicable to other members of the TNFR superfamily, as well as to oligomeric receptors in general.

AB - Tumor necrosis factor receptor 1 (TNFR1) is a transmembrane receptor that binds tumor necrosis factor or lymphotoxin-alpha and plays a critical role in regulating the inflammatory response. Upregulation of these ligands is associated with inflammatory and autoimmune diseases. Current treatments reduce symptoms by sequestering free ligands, but this can cause adverse side effects by unintentionally inhibiting ligand binding to off-target receptors. Hence, there is a need for new small molecules that specifically target the receptors, rather than the ligands. Here, we developed a TNFR1 FRET biosensor expressed in living cells to screen compounds from the NIH Clinical Collection. We used an innovative high-throughput fluorescence lifetime screening platform that has exquisite spatial and temporal resolution to identify two small-molecule compounds, zafirlukast and triclabendazole, that inhibit the TNFR1-induced IκBα degradation and NF-κB activation. Biochemical and computational docking methods were used to show that zafirlukast disrupts the interactions between TNFR1 pre-ligand assembly domain (PLAD), whereas triclabendazole acts allosterically. Importantly, neither compound inhibits ligand binding, proving for the first time that it is possible to inhibit receptor activation by targeting TNF receptor–receptor interactions. This strategy should be generally applicable to other members of the TNFR superfamily, as well as to oligomeric receptors in general.

KW - NF-κB inhibition

KW - pre-ligand assembly domain

KW - receptor–receptor interaction

KW - time-resolved FRET

KW - tumor necrosis factor receptor 1

UR - http://www.scopus.com/inward/record.url?scp=85028431999&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028431999&partnerID=8YFLogxK

U2 - 10.1177/2472555217706478

DO - 10.1177/2472555217706478

M3 - Article

VL - 22

SP - 950

EP - 961

JO - SALAS Discovery

JF - SALAS Discovery

SN - 2472-5552

IS - 8

ER -